Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Review article: Biomedical intelligence

Vol. 140 No. 2728 (2010)

Swiss Consensus Statement: Recommendations for optimising re-treatment with MabThera® (rituximab) in rheumatoid arthritis

  • A Finckh
  • D Kyburz
  • B Möller
  • U Schmiedel
  • P Villiger
  • U Walker
DOI
https://doi.org/10.4414/smw.2010.13073
Cite this as:
Swiss Med Wkly. 2010;140:w13073
Published
05.07.2010

Summary

Rituximab is an effective treatment of rheumatoid arthritis (RA), which has been approved for the treatment of moderate to severe disease in patients with an inadequate response to anti-TNF therapies. Rituximab differs from other available biological agents for RA by way of its unique mode of action and unrivalled long dosing interval. The efficacy of rituximab subsides progressively over time and re-therapy is generally required to maintain long term disease control. The timing of re-treatment is currently not well established and varies widely in clinical practice. The present document is a concise recommendation regarding re-treatment with rituximab, based on validated outcomes such as the DAS28 and the EULAR response criteria. The recommendation was established through consensus between practitioners familiar with rituximab therapy in RA. Optimisation of the rituximab re-treatment schedule may improve patient outcomes and balance risks and benefits for the individual patient.

References

  1. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54(9):2793–806.
  2. Keystone E, Burmester GR, Furie R, Loveless JE, Emery P, Kremer J, et al. Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum. 2008;59(6):785–93.
  3. Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum. 2007;56(12):3896–908.
  4. Keystone EC. Efficacy and safety of repeat treatment courses of rituximab in RA patients with inadequate response to Tumor Necrosis Factor inhibitors: Long-term experience from the REFLEX study [abstract]. Arthritis Rheum. 2008.
  5. Cohen S, E.C. K, Genovese MC, Emery P, Peterfy C, Tak PP, et al. Continued inhibition of structural damage in rheumatoid arthritis patients treated with rituximab at 2 years: REFLEX study (abstract). Ann Rheum Dis. 2008;67(Suppl II):189.
  6. Keystone E, Emery P, Peterfy CG, Tak PP, Cohen S, Genovese MC, et al. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis. 2009;68(2):216–21.
  7. Van Vollenhoven FR, Emery P, Bingham III CO, Keystone EC, Fleishmann RM, Furst DE, et al. Long-term safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol. 2010;37(3):558–67.
  8. van Vollenhoven RF, Emery P, Bingham III CO, Keystone EC, Fleishmann RM, Furst DE, et al. Long-Term Safety of Rituximab: Long-Term Follow-up of the RA Clinical Trials and Retreatment Population [abstract]. Arthritis Rheum. 2009;60(Suppl 10):1952. DOI: 10.002/art.27025.
  9. Finckh A, Courvoisier D, Ciurea A, Brulhart L, Kyburz D, Scherer A, et al. Longterm treatment with RTX in RA: evidence for a learning curve by rheumatologists [abstract]. Ann Rheum Dis. 2009;68 (Suppl 3):438.
  10. Smolen JS, Keystone EC, Emery P, Breedveld FC, Betteridge N, Burmester GR, et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66(2):143–50.
  11. Mease PJ, Cohen S, Gaylis NB, Chubick A, Kaell AT, Greenwald M, et al. Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial. J Rheumatol. 2010;37(5):917–27.
  12. Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis. 2009;68(6):954–60.
  13. Isaacs JD, Olech E, Tak PP, Deodhar A, Keystone E, Emery P, et al. Autoantibody-positive RA patients have enhanced clinical response to RTX when compared with seronegative patients [abstract]. Ann Rheum Dis. 2009;68(Suppl 3):442.
  14. Moller B, Aeberli D, Eggli S, Fuhrer M, Vajtai I, Vogelin E, et al. Class-switched B cells display response to therapeutic B-cell depletion in rheumatoid arthritis. Arthritis Res Ther. 2009;11(3):R62.
  15. Ziswiler HR, Aeberli D, Villiger PM, Moller B. High-resolution ultrasound confirms reduced synovial hyperplasia following rituximab treatment in rheumatoid arthritis. Rheumatology. (Oxford). 2009;48(8):939–43.
  16. Fleischman RM. Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis. Arthritis Rheum. 2009;60(11):3225–28.
  17. Thurlings RM, Vos K, Gerlag DM, Tak PP. Disease activity-guided rituximab therapy in rheumatoid arthritis: the effects of re-treatment in initial nonresponders versus initial responders. Arthritis Rheum. 2008;58(12):3657–64.
  18. Vital EM, Dass S, Rawstron AC, Buch MH, Goeb V, Horner EA, et al. Management of non-response to rituximab in rheumatoid arthritis: predictors and outcome of retreatment. Arthritis Rheum. 2010;doi 10.1002/art.27359.
  19. Bykerk V. Unmet needs in rheumatoid arthritis. J Rheumatol Suppl. 2009;82:42–6.
  20. Drossaers-Bakker KW, de Buck M, van Zeben D, Zwinderman AH, Breedveld FC, Hazes JM. Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum. 1999;42(9):1854–60.
  21. Keystone EC, Fleischmann R, Emery P, Dougados M, Baldassare AR, Armstrong GK, et al. Multiple Courses of Rituximab (RTX) Produce Sustained Efficacy in Patients (pts) with Rheumatoid Arthritis (RA) with An Inadequate Response (IR) to One or More TNF Inhibitors [abstract]. Arthritis Rheum. 2009;60(Suppl 10):1683. DOI: 10.002/art.26757.
  22. Finckh A, Ciurea A, Brulhart L, Moller B, Walker UA, Courvoisier D, et al. Which subgroup of rheumatoid arthritis patients benefits from switching to rituximab versus alternative anti-TNF agents after previous failure to anti-TNF agent? Ann Rheum Dis. 2010;69(2):387–393.
  23. Tak PP, Rigby WF, Rubbert-Roth A, Peterfy CG, van Vollenhoven RF, Stohl W, et al. RTX in combination with MTX significantly inhibits joint damage and improves clinical outcomes in patients with early active RA who are naïve to MTX (IMAGE) [abstract]. Arthritis Rheum. 2009;60(Suppl 10):636 DOI: 10.1002/art.25716.